The Claim
Lower baseline body weight and BMI are associated with a higher probability of achieving a BMI below 30 kg/m² following GLP-1 receptor agonist therapy in adults with obesity and type 2 diabetes.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults with obesity and type 2 diabetes who start GLP-1 receptor agonist therapy with lower body weight and BMI are more likely to reach a BMI below 30 kg/m² than those with higher baseline values.
See the scientific wording
Baseline body weight and BMI are strongly associated with the likelihood of achieving a BMI below 30 kg/m² after GLP-1 receptor agonist therapy, with lower baseline values predicting higher probability of weight improvement in adults with obesity and type 2 diabetes.
People with less body fat respond better to GLP-1 medications because their fat cells are more sensitive to the drug's signals, allowing the body to burn fat more efficiently and lower blood sugar more effectively.
What the research says
1 studyPeople who start with a lower weight and BMI are more likely to get their BMI below 30 after taking GLP-1 medications, and this study found that starting weight and BMI were the best clues for predicting who would succeed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.